Navigation Links
Transforming cancer treatment
Date:7/11/2012

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

Martin Nowak, a Harvard Professor of Mathematics and of Biology and Director of the Program for Evolutionary Dynamics, is one of several co-authors of a paper, published in Nature, that details how resistance to targeted drug therapy emerges in colorectal cancers, and suggests a new, multi-drug approach to treatment could make many cancers manageable, if not curable, illnesses.

The key, Nowak's research suggests, is to change the way clinicians battle the disease.

Though physicians and researchers in recent years have increasingly turned to "targeted therapies" new drugs which combat cancer by interrupting its ability to grow and spread rather than traditional chemotherapy, the treatment is far from perfect. Most are only effective for a few months before the cancer evolves resistance to the drugs and is able to grow unchecked.

In the particular colon cancer treatment that was the subject of Nowak's research, the culprit is the KRAS gene. Normally responsible for producing a protein to regulate cell division, when activated, the gene helps cancer cells develop resistance to targeted therapy drugs, effectively making the treatment useless.

Based on analysis completed by Benjamin Allen, a Post-Doctoral Fellow in Mathematical Biology, and Ivana Bozic, a Post-Doctoral Fellow in Mathematics, Nowak's research suggests that, of the billions of cancer cells that exist in a patient, only a tiny percentage about one in a million are resistant to drugs used in targeted therapy. When treatment starts, the non-resistant cells are wiped out. The few resistant cells, however, quickly repopulate the cancer, causing the treatment to fail.

The answer, Nowak argued, is simple rather than the one drug used in targeted therapy, treatments must involve at least two drugs.

Nowak isn't new to such suggestions in 1995, he participated in a study, also published in Nature, that focused on the rapid evolution of drug resistance in HIV. The end result of that study, he said, was the development of the drug "cocktail" many HIV-positive patients use to help manage the disease.

Ultimately, Nowak estimated that hundreds of drugs might be needed to address all the possible treatment variations. The challenge in the near term, he said, is to develop those drugs. Once available, though, he believes the multi-drug approach offers a new avenue for cancer treatment, one that may fundamentally alter how the public views the disease.

"This will be the main avenue for research into cancer treatment, I think, for the next decade and beyond," Nowak said. "As more and more drugs are developed for targeted therapy, I think we will see a revolution in the treatment of cancer."


'/>"/>

Contact: Peter Reuell
preuell@fas.harvard.edu
617-496-8070
Harvard University
Source:Eurekalert

Related biology news :

1. Preclinical studies use specialized ultrasound to detect presence of cancer
2. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
3. Researchers discover molecule in immune system that could help treat dangerous skin cancer
4. Stanford scientists find molecule to starve lung cancer and improve ventilator recovery
5. Tumor microenvironment helps skin cancer cells resist drug treatment
6. Cancer scientists link ‘oncometabolite’ to onset of acute myeloid leukemia
7. The genomics symposium to boost the further development of cancer research
8. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
9. Regulation of telomerase in stem cells and cancer cells
10. 5th Latin American Conference on Lung Cancer
11. Husband-wife team set out to improve breast cancer exams
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Weeks after ... News in Phoenix, Dr. Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand ... practice. The Wrist MRI machine is a state-of-the-art technology and only 1 of about ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
(Date:5/26/2016)... and READING, England ... Indegene ( http://www.indegene.com ), a leading global provider ... science, pharmaceutical and healthcare organisations and TranScrip ( ... scientific support throughout the product lifecycle, today announced ... launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy ... earlier this year following FDA approval of a second application for a single ...
Breaking Biology Technology: